tirzepatide in osa for Tirzepatide, also known as Mounjaro

Do you have cardiovascular risk factors where tracking improvements would influence other treatment decisions

These agents now have indication to provide cardiovascular benefits, and they show promise in improving kidney and liver health while on GLP-1 treatment, making assessment of cardiometabolic disease critical before, during, and after therapy

To compare, people in the placebo group only lost an average of 2.4% of their starting weight

The dose increases gradually every four weeks

GLP-1s have begun to influence the food landscape in Spain, but their uptake is limited

Our aim was to determine the effects of systemic GLP-1R agonism on the liver